VBI Vaccines Inc.

Belkins
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac® is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

news image

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

news image

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

news image

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

news image

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More
news image

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More
news image

INRAE, EVOLUGATE ENTER OPTION LICENSE AGREEMENT TO ADVANCE PROBIOTICS TO MANAGE HUMAN CHOLESTEROL

Evolugate | May 28, 2020

INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases.INRAE is the first worldwide research institute in agronomy. INRAE-Micalis has been investigating the human microbiome to identify microbes that can influence hypercholesterolemia. They have selected microbes that degrade or sequeste...

Read More
news image

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More
news image

RESEARCH

TETRASCIENCE R&D DATA CLOUD SELECTED BY LEADING CLINICAL-STAGE BIOTECHNOLOGY COMPANY

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data sc...

Read More